e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Dennis Falzon, Ernesto Jaramillo, Christopher Gilpin, Karin Weyer
Source:
Eur Respir J , 49 (4) 1700317; DOI: 10.1183/13993003.00317-2017
Journal Issue:
April
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dennis Falzon, Ernesto Jaramillo, Christopher Gilpin, Karin Weyer. Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis. Eur Respir J , 49 (4) 1700317; DOI: 10.1183/13993003.00317-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Rational use of tuberculosis drugs to prevent the development of drug resistance
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis
Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020
Year: 2021
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
Source: Eur Respir J 2009; 33: 581-585
Year: 2009
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy
Source: Eur Respir J 2001; 17: 641-646
Year: 2001
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon?
Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Year: 2005
Initial antituberculosis drugs resistance
Source: Eur Respir J 2006; 28: Suppl. 50, 12s
Year: 2006
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020
Year: 2020
Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay
Source: Eur Respir J 2013; 41: 1163-1171
Year: 2013
Prevalance of initial and acquired resistance to antituberculosis drugs in our clinic
Source: Eur Respir J 2005; 26: Suppl. 49, 653s
Year: 2005
Evaluation of therapeutic response in isoniazid resistant TB
Source: Eur Respir J 2006; 28: Suppl. 50, 846s
Year: 2006
The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs
Source: Eur Respir J 2002; 20: Suppl. 38, 613s
Year: 2002
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
Source: Eur Respir J 2013; 42: 156-168
Year: 2013
The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007
Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department
Source: Eur Respir J 2003; 22: Suppl. 45, 520s
Year: 2003
A Cuban successful history on antituberculosis treatment and drug resistance surveillance
Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases
Year: 2007
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept